Prostaglandins as putative neurotoxins in Alzheimer's disease

Proceedings of the Society for Experimental Biology and Medicine

Volumn 219, Issue 2, 1998, Pages 120-125

  Prasad, Kedar N ^a   Hovland, Alicia R ^a   La Rosa, Francisco G ^a   Hovland, Peter G ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ALPHA TOCOPHEROL; AMYLOID BETA PROTEIN; ANTIOXIDANT; BETA CAROTENE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN A1; PROSTAGLANDIN E1; UBIQUITIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CONFERENCE PAPER; DEGENERATIVE DISEASE; FETUS; MOUSE; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN ANALYSIS; PROTEIN BINDING; RAT;

ANIMALIA; MURINAE;

EID: 0031670924     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.3181/00379727-219-44323     Document Type: Conference Paper

References (82)

1. Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol 125:420-436, 1987.
2. Schoenberg BS, Kokmen E, Okazaki H. Alzheimer's disease and other dementing illnesses in a defined United States population: Incidence rates and clinical features. Ann Neurol 22:724-729, 1987.
3. Evans DA, Frankenstein HH, Albert MS. Prevalence of Alzheimer's disease in a community population of older persons higher than previously reported. JAMA 262:2551-2556, 1989.
4. Anderson K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease. Neurology 45:1441-1445, 1995.
5. Rogers J, Singer RH, Luber-Narod J, Bassell GJ. Neurovirologic and neuroimmunologic considerations in Alzheimer's disease. Neuroscience 12a:944, 1986.
6. Shalit F, Sredni B, Stern B, Stern L, Kott E, Huberman M. Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients. Neurosci Lett 174:130-132, 1994.
7. Sharif SF, Hariri RJ, Chang VA, Barie PS, Wang RS, Ghajar JB. Human astrocyte production of tumor necrosis factor-α, interleukin-1 β and interleukin-6 following exposure to lipopolysaccharide endotoxin. Neurol Res 15:109-112, 1993.
8. Rogers J, Lue L-F, Brachova L, Webster S, Schultz J. Inflammation as a response and a cause of Alzheimer's pathophysiology. Dementia 9:133-138, 1995.
9. Kuby J. Immunology. New York: W.H. Freeman and Company, pp393-411, 1994.
10. Rogers J, Cooper NR, Webster S, Schultz J, McGreer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P, Lieberburg I. Compliment activation by β-amyloid in Alzheimer's disease. Proc Natl Acad Sci USA 89:10016-10020, 1992.
11. Eikelenboom P, Stam FC. Immunoglobulins and compliment factors in senile plaques. Acta Neuropathol 57:239-242, 1982.
12. Eikelenboom P, Stam FC. An immunohistochemical study on cerebral and senile plaque amyloid in Alzheimer's disease dementia. Virch Arch B (Cell Pathol) 47:17-25, 1984.
13. Eikelenboom P, Hack DE, Rozenmuller JM, Stam FC. Compliment activation in amyloid plaques in Alzheimer's disease but not scrapie-affected mice are closely associated with a local inflammatory process. Virch Arch B (Cell Pathol) 60:329-336, 1989.
14. Eikelenboom P, Zhan SS, Kamphorst W, Van der Alk P, Rozenmuller JM. Cellular and substrate adhesion molecules (integrins) and their ligands in cerebral amyloid plaque in Alzheimer's disease. Virch Arch B (Cell Pathol) 424:421-427, 1994.
15. Lue L-F, Rogers J. Full compliment activation fails to diffuse plaques of the Alzheimer's disease cerebellum. Dementia 3:308-313, 1992.
16. Webster S, O'Barr S, Rogers J. Enhanced aggregation and βstructure of amyloid βpeptide after co-incubation with C1q. J Neurosci Res 39:448-456, 1994.
17. Anderton B. Free radicals on the mind: Hydrogen peroxide-mediated amyloid β protein toxicity. Hum Exp Toxicol 13:719a, 1994.
18. Chen L, Richardson JS, Caldwell JE, Ang LC. Regional brain activity of free radical defense enzymes in autopsy samples from patients with Alzheimer's disease and from nondemented controls. Int J Neurosci 75:83-90, 1994.
19. Evans PH. Free radicals in brain metabolism and pathology. B Med Bull 49:577-587, 1993.
20. Gotz ME, Kunig G, Riederer P, Youdim MB. Oxidative stress: Free radical production in neural degeneration. Pharmacol Ther 64:37-122, 1994.
21. Olanow CW, Arendash GW. Metals and free radicals in neurodegeneration. Curr Opin Neurol 7:548-558, 1994.
22. Richardson JS, Subbarao KV, Ang LC. On the possible role of iron-induced free radical peroxidation in neural degeneration in Alzheimer's disease. Ann NY Acad Sci 64:326-327, 1992.
23. Smith MA, Sayre LM, Monnier VM, Perry G. Radical ageing in Alzheimer's disease. Trends Neurosci 18:172-176, 1995.
24. Harman D. Free radical theory of aging: Alzheimer's disease and pathogenesis. Age 18:97-119, 1995.
25. Frohman EM, Frohman TC, Gupta S, de Fougerolles A, van den Noort S. Expression of intracellular adhesion molecule-1 (ICAM-1) in Alzheimer's disease. J Neurosci 106:105-111, 1991.
26. Verbeek MM, Otte-Holler I, Westphal JR, Wesseling P, Ruiter DJ, de Waal RM. Accumulation of intracellular adhesion molecule-1 in senile plaques in brain tissue of patients with Alzheimer's disease. Am J Pathol 144:104-116, 1994.
27. Rozenmuller JM, Eikelenboom P, Pals ST, Stam FC. Microglia cells around amyloid plaques in Alzheimer's disease express leukocyte adhesion molecules of the LFA-1 family. Neurosci Lett 101:228-292, 1989.
28. Rosenman SJ, Shrikant P, Dubb L, Benveniste EN, Ransohoff RM. Cytokine-induced expression of vascular cell adhesion molecule-1 (VCAM-1) by astrocytes and astrocytoma cell lines. J Immunol 154:1888-1889, 1995.
29. Yankner BA, Mesulam MM. β-amyloid and the pathogenesis of Alzheimer's disease. New Eng J Med 325:1849-1857, 1991.
30. Hardy T, Allsop D. Amyloid deposition as the cerebral even in the etiology of Alzheimer's disease. Trend Pharmacol Sci 12:383-388, 1991.
31. Joachim CL, Selkoe DJ. The seminal role of β-amyloid is the pathogenesis of Alzheimer's disease. Alzheimer Dis Assoc Disord 6:7-34, 1992.
32. Selkoe DJ. Cell biology of the amyloid-β protein precursor and the mechanism of Alzheimer's disease. Annu Rev Cell Biol 10:373-403, 1994.
33. Dewzi NN, Singer SJ. Genetic clues to Alzheimer's disease. Science 271:159-160, 1996.
34. Wang GP, Khatoon S, Iqbal K, Grunke-Iqbal I. Brain ubiquitin is markedly elevated in Alzheimer's disease. Brain Res 566:146-151, 1991.
35. Kudo T, Iqbal K, Ravid R, Swaab DF, Grundke-Iqbal I. Alzheimer's disease: Correlations of cerebrospinal fluid and brain ubiquitin levels. Brain Res 649:1-7, 1994.
36. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375:754-760, 1995.
37. Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al. Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376:775-778, 1995.
38. Prasad KN, Kentroti S, Edwards-Prasad J, Vernadakis A, Imam M, Carvalho E, Kumar S. Modification of the expression of adenosine 3′,5′-cyclic monophosphate-induced differentiated functions in neuroblastoma cells by β carotene and d-α-tocopheryl succinate. J Am Coll Nutr 13:298-303, 1994.
39. Prasad KN, La Rosa FG, Prasad JE. Prostaglandins act as neurotoxin for differentiated neuroblastoma cells in culture and increase levels of ubiquitin and β-amyloid. In Vitro Cell Dev Biol 834:265-274, 1998.
40. Prasad KN. Morphological differentiation induced by prostaglandins in mouse neuroblastoma cells in culture. Nature New Biol 236:49-51, 1972.
41. Prasad KN. Differentiation of neuroblastoma cells: A useful model for neurobiology and cancer. Biol Rev 66:431-451, 1991.
42. 1 inhibition of chondrosarcoma growth. Biochem Biophys Res Commun 60:1302-1308, 1974.
43. Santoro MG, Benedetto A, Jaffe BM. Prostaglandin A, induces differentiation in Friend erythroleukemia cells. Prostaglandins 17:719-727, 1979.
44. Karmali RA. Prostaglandins and cancer. Prostaglandins Med 5:11-28, 1980.
45. Hazuka MB, Edwards-Prasad J, Newman F, Kinjie JJ, Prasad KN. β-carotene induces morphological differentiation and decreases adenylate cyclase activity in melanoma cells in culture. J Am Coll Nutr 9:143-149, 1990.
46. Prasad KN, Edwards-Prasad J,-Kentroti S, Freed C. Production of terminally differentiated neuroblastoma cells for neural transplant studies. Res Neurobiol Neurosci 7:13-19, 1994.
47. Selkoe DJ, Xia W, Zhang J, Koo EH. In vivo interactions between amyloid precursor protein and presenilins. Soc Neurosci 23:2949, 1997.
48. Capell A, Wild-Bode C, Yamazaki T, Steiner H, Ihara Y, Haass C. Cleavage of amyloid β-peptide at amino acid 42 occurs within the endoplasmic reticulum. Soc Neurosci 23:293a, 1997.
49. Araufo DM, Cotman CW. β-Amyloid stimulates glia cells in vitro to produce growth factors that accumulate in senile plaques in Alzheimer's disease. Brain Res 569:141-145, 1992.
50. Gitter BD, Cox LM, Rydel RE, May PC. Amyloid β peptide potentiates cytokine secretion by interleukin-1 β-activated human astrocytoma cells. Proc Natl Acad Sci USA 92:10738-10741, 1995.
51. 4 amyloid protein precursor. Proc Natl Acad Sci USA 89:10075-10078, 1992.
52. Forloni G, Demicheli F, Giorgi S, Bendotti C, Angeretti N. Expression of amyloid precursor protein mRNAs in endothelial, neuron, and glia cells: Modulation by interleukin-1. Mol Brain Res 16:128-134, 1992.
53. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP, Gajdusek DC. Interleukin 1 regulates synthesis of amyloid β-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 86:7606-7610, 1989.
54. Gray CW, Patel AJ. Regulation of β-amyloid precursor protein isoform mRNAs by transforming growth factor β1 and interleukin-1β in astrocytes. Mol Brain Res 19:255-256, 1993.
55. Gegelashvili G, Bock E, Schousboe A, Linneman D. Two types of amyloid precursor protein (APP) mRNA in rat glioma cell lines: Up-regulation via a cyclic AMP-dependent pathway. Brain Res Mol Brain Res 37:151-156, 1996.
56. Bourbonniere M, Shekarabi M, Nalbantoglu J. Enhanced expression of amyloid precursor protein in response to dibutyryl cyclic AMP is not mediated by the transcription factor AP-2. J Neurochem 68:909-916, 1997.
57. La Rosa FG, Kuma S, Prasad KN. Increased expression of ubiquitin during adenosine 3′,5′-cyclic monophosphate-induced differentiation of neuroblastoma cells in culture. J Neurochem 66:1845-1860, 1996.
58. Gregory L, Hainfield JF, Simon MN, Goldgaber D. Amyloid β protein binds the eukaryotic 20 S proteosome. Soc Neurosci 22:502a, 1996.
59. Rechsteiner M. Ubiqutin-mediated pathways for intracellular proteolysis. Annu Rev Cell Biol 3:1-10, 1987.
60. Mon H, Kondo L, Ihara Y. Ubiquitin and the enigma of intracellular protein degradation. Eur J Biochem 231:1-30, 1987.
61. Lowe J, Blanchard A, Morrell K, Lennox G, Reynolds L, Billet M, Landon M, Mayer J. Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and Mallory bodies in alcoholic liver disease. J Pathol 155:9-15, 1988.
62. Kim H, Gearing M, Mirra SS. Ubiquitin-positive CA2/3 neuntes in hippocampus coexist with cortical Lewy bodies. Neurology 45:1768-1770, 1995.
63. Morishima-kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K, Ihara Y. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10:1151-1160, 1993.
64. Soldatenkov VA, Dritschilo A. Apoptosis of Ewing's sarcoma cells is accompanied by accumulation of ubiquitinated proteins. Cancer Res 57:3881-3885, 1997.
65. LaFerla FM, Tronsco JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular A β stabilization. J Clin Invest 100:310-320, 1997.
66. Grundke-Iqbal I, Iqbal K, George L, Tung YC, Kim KS, Wisniewski HM. Amyloid protein and neurofibrillary tangles coexist in the same neuron in Alzheimer disease. Proc Natl Acad Sci USA 86:2853-2857, 1989.
67. Perry G, Cras P, Siedlak SL, Tabaton M, Kawai M. β protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am J Pathol 140:283-289, 1992.
68. Maruyama K, Terakado K, Usami M, Yoshikawa K. Formation of amyloid-like fibrils in COS cells overexpressing part of the Alzheimer amyloid protein precursor. Nature (Lond) 347:566-569, 1990.
69. Martin LJ, Pardo CA, Cork LC, Price DL. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am J Pathol 145:1358-1381, 1994.
70. Cummings BJ, Su JH, Cotman CW, White R, Russell MJ. β-Amyloid accumulation in aged canine brain: A model of early plaque formation in Alzheimer's disease. Neurobiol Aging 14:547-560, 1993.
71. McGeer PL, McGeer EG, Rogers J, Sibley J. Anti-inflammatory drugs and Alzheimer's disease. Lancet 335:1037, 1990.
72. Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 36:854-856, 1994.
73. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGreer PL, Kaszniak AW, Zalinski J, Cofield M, Mansukhani L, Wilson P, Kogan F. Clinical trial of indomethacin in Alzheimer's disease. Neurology 43:1609-1611, 1993.
74. Breitner JCS, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helmas MJ, Anthony JC. Inverse association of anti-inflammatory treatments and Alzheimer's disease. Neurology 44:227-232, 1994.
75. 2 blocking drugs. Neurobiol Aging 16:523-530, 1995.
76. Broe GA, Henderson AS, Creasey H, McCusker E, Korten HE, Jorm AF, Longley W, Anthony JC. A case-control study of Alzheimer's disease in Australia. Neurology 40:1698-1707, 1990.
77. Graves AB, White E, Koepsell TD, Reifler BV, Van Belle G, Larson EB, Raskind M. A case-control study of Alzheimer's disease. Ann Neurol 28:766-774, 1990.
78. Jenkinson MI, Bliss MR, Brain AT, Scott DL. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol 28:86-87, 1989.
79. Li G, Shen YC, Chen CH, Zhau YW, Silverman JM. A case-control study of Alzheimer's disease in China. Neurology 42:1481-1482, 1992.
80. Mylly Kangas-Lousu Jarvi R, Isomaki H. Alzheimer's disease and rheumatoid arthritis. Br J Rheumatol 33:501-502, 1994.
81. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45:51-55, 1995.
82. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. N Eng J Med 336:1216-1222, 1997.